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1 
2 
3 ABSTRACT 
4 
5 
6 [Aim] XG-102 is a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase. With 
7 
8 a molecular weight of 5000 and a resistance to proteases, we hypothesized that XG-102 could be 
9 
10 used locally as a long acting anti-inflammatory agent. We tested different routes of administra- 
11 
12 
13 tion and doses in rat endotoxin-induced uveitis (EIU). 
14 
15 [Methods] XG-102 was administered at the time of LPS challenge either by intravenous (IV; 3.2, 
16 
17 35 or 355 µg/injection), intravitreous (IVT; 0.08, 0.2 or 2.2 µg/eye) or sub-conjunctival (SCJ; 
 
19 
20 0.2, 1.8 or 2.2 µg/eye) injections. Controls received either the vehicle or Dexamethasone phos- 
21 
22 phate injections. Efficacy was assessed by clinical scoring, infiltrating cells count, and expression 
23 
24 of inflammatory mediators (iNOS, CINC-1). Effect of XG-102 on phosphorylated c-Jun was 
26 
27 evaluated on Western-bolt. 
28 
29 [Results] XG-102 clinically demonstrated a dose-dependent anti-inflammatory effect in EIU af- 
30 
31 
32 ter IV and SCJ administrations. The respective doses of 35 µg and 1.8 µg were efficient as com- 
33 
34 pared with the vehicle-injected controls, but only the highest doses, respectively 355 µg and 22 
35 
36 µg, were as efficient as Dexamethasone. IVT injections of XG-102 at all tested doses was as effi- 
37 
38 
39 cient as dexamethasone. The clinical effect of XG-102 correlated well with reduction of c-Jun N- 
40 
41 terminal kinase activity; infiltration of cells and iNOS and CINC-1 expression. 
42 
43 [Conclusion] Local administration of XG-102 can be used as efficiently as systemic route for the 
45 
46 treatment of ocular inflammation.  results confirm that XG-102 have potential for treating intra- 
47 
48 ocular inflammation. 
49 
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1 
2 
3 Introduction 
4 
5 
6 Intraocular inflammation has an annual incidence of 52 cases per 100,000, resulting in a preva- 
7 
8 lence of about 115 per 100,000 [1]. Acute anterior uveitis (AAU) is by far the most common 
9 
10 form of uveitis representing around 80% of the cases. Its recurrent nature may result in secondary 
11 
12 
13 complications such as cataract, cystoid macular edema, glaucoma and, ultimately, destruction of 
14 
15 the intraocular tissues and blindness [Error! Reference source not found., Error! Reference source 
16 
17 
not found.]. Current treatments for uveitis include corticosteroids [Error! Reference source not 
19 
20 found.], immunosuppressive agents as tumor-necrosis factor-alpha (TNF-α) inhibitors and cyclo- 
21 
22 sporine in corticosteroid-resistant cases, or chemotherapeutic agents as cyclophosphamide in se- 
24 
25 vere uveitis. These pharmacological agents are delivered through topical and peri-ocular routes in 
26 
27 AAU that are not associated with systemic diseases. Corticosteroids agents show clear clinical 
28 
29 
30 benefits but their chronic use is associated with many sight-threatening side effects, such as glau- 
31 
32 coma, cataract, whilst systemic immunosuppressive agents are associated with general side- 
33 
34 effects [1, Error! Reference source not found.]. Given these restrictions, there is an obvious demand 
35 
36 
37 for the development of new local therapeutic strategies [Error! Reference source not found.]. 
38 
39 Current clinical trials concern the development of sustained-release delivery system like cortico- 
40 
41 steroid intravitreal implants [Error! Reference source not found.], as well as new immunosuppres- 
43 
44 sive drugs, as anti-pro-inflammatory cytokines: new anti-TNF-α agents, interleukin (IL) recep- 
45 
46 tors as IL-6R and IL-1R, interferon-gamma (IFN- γ) antagonists…[Error! Reference source not 
48 
49 found., clinicaltrials.gov].  Many of the gene products involved in the inflammatory response are 
50 
51 regulated by the transcription factor activator protein-1 (AP-1) and the c-Jun NH2-terminal kinase 
52 
53 
54 (JNK) pathways: TNF-α, IFN-γ, IL-2, membrane cofactor protein-1 (MCP-1), macrophage in- 
56 
57 
58 
59 
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1 
2 
3 flammatory protein-1 alpha (MIP-1α), cyclooxygenase-2 (COX-2), inducible nitric oxide syn- 
4 
5 
6 thase (iNOS)… 
7 
8 Among all the anti-inflammatory strategies in development, JNK inhibitors have been shown 
9 
10 effective in various models of inflammation [Error! Reference source not found., Error! Reference 
12 
13 source not found.] and could therefore be an interesting alternative to corticosteroid treatments in 
14 
15 AAU. XG-102 is a TAT-coupled dextrogyre peptide which selectively inhibits the c-Jun N- 
16 
17 
18 terminal kinase in vitro. This peptide contains a 20-amino acid sequence of the JNK binding do- 
19 
20 main of islet-brain-1 (IB-1)/JNK-interacting protein-1 (JIP-1), a scaffold protein, combined to a 
21 
22 10-amino acid TAT sequence of the HIV TAT protein, allowing its intracellular penetration. The 
23 
24 
25 D-retro-inverso peptide - the reversed sequence of the D-amino acid form - retains the capacity of 
26 
27 JNK inhibition and translocation, but has an extended activity due to its resistance to degradation 
28 
29 by proteases [Error! Reference source not found.]. 
31 
32 In a previous study, we brought the proof of principle that XG-102, administered either via in- 
33 
34 travitreous (IVT) or intraveinous (IV) injections, efficiently inhibited intraocular inflammation in 
35 
36 
37 a rat model of endotoxin-induced uveitis (EIU) [Error! Reference source not found.]. In the 
38 
39 prospect of a clinical trial, we evaluate herein different doses and routes and compare them to 
40 
41 sub-conjunctival (SCJ) injections. 
42 
43 
44 
45 
46 Material and Methods 
47 
48 Animals 
50 
51 Seven-week-old female Lewis rats (Elevage Janvier, Le Genest Saint Isle, France), weighing 
52 
53 around 175 g, were used for experiments. All animals were treated according to the European 
54 
55 
56 
57 
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1  Convention and to the Association for Research in Vision and Ophthalmology (ARVO) State- 
2 
3 ment for the Use of Animals in Ophthalmic and Vision Research (French decree No.2001-486, 
4 
5 
6 dated June 06, 2001). Rats were anesthetized with intramuscular injection of ketamine (Ketamine 
7 
8 Virbac®, 88 mg/kg; Virbac, France) and chlorpromazine (Largactil®, 0.6 mg/kg; Sanofi-Aventis, 
9 
10 Paris, France) before IV or ocular injections. Rats were sacrificed by a lethal dose of pentobarbi- 
11 
12 
13 tal. 
14 
15 Endotoxin-Induced Uveitis (EIU) induction and experimental design 
16 
17 EIU is a model of acute and predominately anterior uveitis in rats [13]. Eighty two female Lewis 
 
19 
20 rats were randomly divided into fifteen groups of three to nine animals each. EIU was induced by 
21 
22 a single footpad injection of 100 µL sterile pyrogen-free saline containing 200 µg of lipo- 
23 
24 polysaccharide (from Salmonella typhimurium, Sigma-Aldrich, France). Animals were treated 
26 
27 with XG-102 immediately before EIU induction by IV injection (100 µL), or by local (SCJ or 
28 
29 IVT) injectionsin the right eye (5 µL). Contralateral left eyes were not treated. XG-102-treated 
30 
31 
32 rats were compared with control uveitic rats injected with the vehicle (NaCl 0.9%) or with Dex- 
33 
34 amethasone phosphate that was used as positive control for anti-inflammatory activity on EIU. 
35 
36 Clinical ocular inflammation was scored 24 hours after EIU induction. At this time-point, retinal 
37 
38 
39 pigment epithelium (RPE)-choroid-sclera complexes and neuroretinas were carefully dissected 
40 
41 from the enucleated eyes, snap frozen, and stored at -80°C until use, respectively, for the analysis 
42 
43 of c-Jun phosphorylation state by Western blot and for evaluation of inflammatory mediators 
45 
46 (iNOS and cytokine-induced neutrophil chemoattractant-1 (CINC-1)) expression by RT-PCR. 
47 
48 Tissues were collected from eyes treated with XG-102,with the vehicle and non injected eyes. 
49 
50 
51 Three eyes collected from these groups were kept to evaluate inflammatory cell infiltration in 
52 
53 ocular tissues. 
54 
55 Solutions and Injections 
56 
57 
58 
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1 
2 
3 XG-102   peptide   was   produced   and   purified   by   Polypeptide   Laboratories   (Strasbourg, 
4 
5 
6 France).Once lyophilized; XG-102 powder was dissolved in the vehicle (NaCl 0.9%, Versol; 
7 
8 Aguettant, Lyon, France) at the concentration of 5 mg/mL under sterile conditions, and stored at - 
9 
10 80°C until use. For each experiment, XG-102 solutions were prepared extemporaneously at the 
11 
12 
13 required concentration in the vehicle. A fraction of each diluted solution was stored at -80°C until 
14 
15 its assay by HPLC. A commercial solution of Dexamethasone phosphate at 4 mg/mL (Soludeca- 
16 
17 dron; Laboratoire Roussel, Paris, France) was used as positive control. 
 
19 
20 In our previous study, the anti-inflammatory effect of XG-102 in EIU was demonstrated with IV 
21 
22 dose of 20 µg/kg (3.5 µg/rat weighting 175 mg) and IVT dose of 0.2 µg/eye [12]. Based on these 
23 
24 results, three doses were chosen per route of administration. Three solutions were prepared at 32, 
26 
27 350 and 3550 µg/mL for IV injections. For the local treatments, three dilutions per type of injec- 
28 
29 tions were prepared: XG-102 solutions at 17.43 and 430 µg/mL for IVT injections and solutions 
30 
31 
32 at 30, 360 and 4400 µg/mL for SCJ injections. 
33 
34 For  the  systemic  treatment  evaluation,  100  µL  of  vehicle,  Dexamethasone  phosphate  (400 
35 
36 µg/injection) or XG-102 (3.2, 35 or 355 µg/injection) were injected in the tail vein with a 25- 
37 
38 
39 gauge needle connected to a 1 mL syringe (Becton Dickinson, Le Pont de Claix, France). For the 
40 
41 local delivery study, 5 µL of vehicle Dexamethasone phosphate (20 µg/eye) or XG-102 solutions 
42 
43 were injected in the right eye using a 30-gauge disposable needle (BD-microfine syringes; nm 
45 
46 Medical, Asnière, Paris, France). In the XG-102-treated groups, right eyes received 0.08, 0.2 or 
47 
48 2.2 µg of XG-102 through IVT injection, and 0.2, 1.8 or 22 µg through SCJ injection. 
49 
50 
51 Clinical assessment of EIU 
52 
53 Clinical examinations were performed by slit lamp microscopy 24 hours after EIU induction. The 
54 
55 severity of uveitis was scored, in a masked manner, on a scale from 0 to 5 for each eye, as de- 
56 
57 
58 scribed previously [15] grade 0, no inflammation; grade 1, minimal iris and conjunctival vasodi- 
59 
60 
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1 
2 
3 lation but without the observation of flare or cells in the anterior chamber; grade 2, moderate iris 
4 
5 
6 and conjunctival vessel dilation but without evident flare or cells in the anterior chamber; grade 
7 
8 3, intense iris vessels dilation, flare, and fewer than 10 cells per slit lamp field in the anterior 
9 
10 chamber; grade 4, more severe clinical signs than grade 3, with cells in the anterior chamber, with 
11 
12 
13 or without the formation of hypopion; grade 5, intense inflammatory reaction, fibrin formation in 
14 
15 the anterior chamber, and total seclusion of the pupil. 
16 
17 
18 
19 
20 Western Blot analysis of the phosphorylated form of c-Jun (phospho c-Jun) 
21 
22 RPE-choroid-sclera complexes were snap frozen immediately after dissection and stored at -80°C 
23 
24 until use. Tissues were homogenized in 500 µL of lysis buffer, consisting in MOPS SDS Running 
26 
27 Buffer (Invitrogen, Cergy Pontoise, France) supplemented with a cocktail of protease (Roche 
28 
29 Diagnostics, Meylan, France) and phosphatase (Sigma-Aldrich, St-Quentin Fallavier, France) 
30 
31 
32 inhibitors. After heating for 5 min at 100°C, equal amounts of proteins were separated by elec- 
33 
34 trophoresis in a NuPAGE 4-12% Bis-Tris gel (Invitrogen) using MOPS SDS Running Buffer. 
35 
36 The bands obtained were then electroblotted onto a nitrocellulose membrane (Schleicher & 
37 
38 
39 Schuell BioScience, Dassel, Germany). Blots were sequentially incubated with a rabbit anti- 
40 
41 Phospho-c-Jun (Ser 63) primary antibody and an anti-rabbit IgG horseradish peroxidase (HRP)- 
42 
43 linked secondary antibody according to the manufacturer’s instruction (Cell Signaling Technolo- 
45 
46 gy, Ozyme, St Quentin en Yvelines, France). Bands were visualized using the ECL Western Blot- 
47 
48 ting Detection Reagents Kit (Amersham Biosciences, Orsay, France). Blots were then dehybrid- 
49 
50 
51 ized and rehybridized successively with a mouse monoclonal anti α-tubulin primary antibody 
52 
53 (1:400; Serotec, Düsseldorf, Germany) and a HRP conjugated goat anti-mouse IgG secondary 
54 
55 antibody (1:5000; Santa Cruz Biotechnology, Tebu-bio, Le Perray en Yvelines, France). The 
56 
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1 
2 
3 relative band intensity for phospho c-Jun was calculated in comparison to that for α-tubulin after 
4 
5 
6 densitometry analysis (on ImageJ software). 
7 
8 Evaluation of inflammatory cells infiltration using immuno-histochemistry 
9 
10 For immunohistochemical analysis, eyeballs were enucleated, fixed for 1 hour at room tempera- 
11 
12 
13 ture in phosphate-buffered saline (PBS) containing 4% paraformaldehyde and rinsed overnight in 
14 
15 PBS. After careful orientation,samples were embedded in optimal cutting temperature compound 
16 
17 (Tissue-Tek; Sakura Finetek, Zoeterwoude, The Netherlands) and stored at -80°C. Frozen 10-µm 
 
19 
20 sections were collected on Superfrost slides (Gerhard Menzel, Brauschweig, Germany) using a 
21 
22 cryostat (CM 3050S; Leica, Rueil-Malmaison, France). The frozen 10-µm sections collected at 
23 
24 the optic nerve level were stained 5 min with 4’, 6 diamidino-2-phenylindole solution (DAPI, 
26 
27 1:5000; Sigma-Aldrich), mounted in PBS:Glycerol (1:1) and examined with a fluorescence mi- 
28 
29 croscope Olympus BX51 (Rungis, France) coupled with a digital camera Olympus DP70. Poly- 
30 
31 
32 morphonuclear (PMN) cells, identified by the shape of their nuclei stained with DAPI, were 
33 
34 quantified on three different frozenslides per eye (n=3 eyes per group). Results were expressed as 
35 
36 mean ± SEM. 
37 
38 
39 
40 
41 Evaluation of inflammatory mediators expression (iNOS, CINC-1) using RT PCR 
42 
43 Selected doses of XG-102 were used to evaluate the expression of iNOS mRNA (3.2 and 35 µg for IV 
44 
45 
46 injection, 0.2 and 2.2 µg for IVT and 1.8 µg for SCJ injection) and CINC-1 mRNA in eyes (35 µg for IV 
47 
48 injection, 0.2 µg for IVT and 1.8 µg for SCJ injection). 
49 
50 Total RNA was extracted from the neuroretinas stored at -80°C according to the manufacturer’s 
51 
52 instructions (RNeasy minikit, Qiagen, France). For each sample, 1 µg total RNA was readjusted 
53 
54 
55 according to the RNA optic density at 260 nm and transcribed in a total volume of 20 µL using 
56 
57 
58 
59 
60 
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1 
2 
3 Superscript II Reverse Transcriptase (Invitrogen, France) following the manufacturer’s instruc- 
4 
5 
6 tions. 
7 
8 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), iNOS and CINC-1 cDNA were amplified 
9 
10 in a total volume of 25 µL containing 2 µL of first-strand reaction product, 0.4 µM of each primer 
11 
12 
13 (sense and antisense), 0.4 µM dNTP Mix, 1.5 mM MgCl2, 1X PCR buffer and 2.5 U Taq DNA 
14 
15 polymerase (Invitrogen, France). Primers specific for GAPDH (sense: 5’- 
16 
17 ATGCCCCCATGTTTGTGATG-3’; antisense: 5’-ATGGCATGGACTGTGGTCAT-3’), primers 
 
19 
20 specific for CINC-1 (sense: 5’-GGGTGTCCCCAAGTAATGGA-3’; anti-sense: 5’- 
21 
22 CAGAAGCCAGCGTTCACCA-3’) and primers specific for iNOS (sense: 5’- 
23 
24 TTTCTCTTCAAAGTCAAATCCTACCA-3’; antisense: 5’- 
26 
27 TGTGTCTGCAGATGTGCTGAAAC-3’) were obtained from Invitrogen. After an initial dena- 
28 
29 turation (1 min at 94°C), 34 to 37 PCR cycles of denaturation (30 s at 94°C), annealing (1 min at 
30 
31 
32 58°C for GAPDH, at 60°C for CINC and at 52°C for iNOS) and elongation (1-2 min at 72°C) 
33 
34 were performed on a Crocodile III (Appligene-Oncor). The final cycle was completed by 5 min 
35 
36 of elongation at 72°C. PCR fragments (162 bp for GAPDH,53 bp for CINC and 657 bp for iN- 
37 
38 
39 OS) were analyzed by 2.5% agarose gel electrophoresis and visualized by ethidium bromide 
40 
41 staining under ultraviolet light. The relative bands intensity for CINC-1 and iNOS were calculat- 
42 
43 ed in comparison to that for GAPDH after densitometry analysis using ImageJ software. 
45 
46 
47 
48 Statistical analysis 
49 
50 
51 Numerical results were expressed as mean ± standard error mean (SEM) and compared using the 
52 
53 nonparametric Mann-Whitney U-test. P <0.05 was considered statistically significant. 
54 
55 
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1 
2 
3 Results 
4 
5 
6 XG-102 clinical effect on EIU using different routes of administration 
7 
8 Clinical scores were evaluated 24 hours after EIU induction which is the peak of inflammation in 
9 
10 this model. Using either IV or SCJ injections (Fig 1 A and C), a dose-response effect was ob- 
11 
12 
13 served: the lowest doses (3.2 µg for IV and 0.2 µg for SCJ) were not efficient; increasing the 
14 
15 dose induced increased anti-inflammatory effects. At the highest tested doses (355 µg IV, 2.2 µg 
16 
17 IVT and 22 µg SCJ), the anti-inflammatory effects of XG-102 observed were better or equivalent 
 
19 
20 to Dexamethasone phosphate, used as a positive control. The highest SCJ dose (22 µg) also sig- 
21 
22 nificantly reduced inflammation in the contra lateral uninjected eye, suggesting a systemic pas- 
23 
24 sage of XG-102 at high dose. Using IVT injections, all tested doses significantly reduced intraoc- 
26 
27 ular inflammation with the same efficacy as Dexamethasone phosphate but with a reverse dose- 
28 
29 response effect: the higher the dose, the less efficient is the drug (Fig 1B). 
30 
31 
32 
33 
34 Effect of XG-102 on in vivo JNK phosphorylation 
35 
36 Western-blot analysis of the RPE-choroid-sclera complex collected at the peak of the disease 
37 
38 
39 demonstrated a reduced phosphorylation of c-Jun on Ser63 residue, using IV, SCJ and IVT (Fig 
40 
41 2). The densitometry analysis of Western blot showed a decrease in State of c-Jun phosphorylation 
42 
43 in the samples either after 35 µg-XG-102 IV injection (0.284 vs 2.075 in vehicle IV; Fig 2A) or 
45 
46 1.8 µg-XG-102 SCJ injection (0.222 vs 1.436 in vehicle SCJ; Fig 2C). In the same manner, a 
47 
48 reduction of c-Jun phosphorylation was observed in RPE-choroid-sclera complex after 0.2 µg- 
49 
50 
51 XG-102 IVT injection (0.205 vs 1.086 in vehicle IVT; Fig 2B). 
52 
53 
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1 
2 
3 Effect of XG-102 on ocular cell infiltration 
4 
5 
6 Identified by the shape of their nuclei, stained with DAPI, polymorphonuclear cells (PMN) cells 
7 
8 were quantified on histological sections of the ocular tissues. One day after 35 µg-XG-102 IV 
9 
10 delivery, the PMN cells infiltration decreased by 38% compared with vehicle IV injection (342 ± 
11 
12 
13 50 vs 552 ± 151, Fig 3A). Using IVT, 0.2 µg-XG-102 delivery decreased by 48% the number of 
14 
15 infiltrating cells as compared with the vehicle-injected eyes (97 ± 38 vs186 ± 65, Fig 3B). XG- 
16 
17 102 SCJ administration decreased by 57% the PMN infiltration in the eyes treated with1.8 µg 
 
19 
20 XG-102 as compared with the vehicle delivery (177 ± 41 vs 415 ± 87, Fig 3C). 
21 
22 
23 
24 
25 Expression of pro-inflammatory mediators 
26 
27 XG-102 reduced iNOS expression in ocular tissues whatever the route of administration. 
28 
29 In comparison with the vehicle-injected eyes, IV injections of 35 µg XG-102 led to the downreg- 
30 
31 
32 ulation of iNOS mRNA from1.067 ± 0.037 to 0.390 ± 0.218 (-64%, Fig 4A). In IVT injected eyes 
33 
34 with 0.2 µg of XG-102, a 98% reduction in iNOS expression was observed (from 1.040 ± 0.001 
35 
36 to 0.02 ± 0.03, Fig4B) and 92% with 2.2 µg XG-102 (from 1.04 ± 0.001 to 0.086 ± 0.06). Using 
37 
38 
39 SCJ delivery injection, iNOS expression decreased significantly by 86% in the right eyes treated 
40 
41 with 1.8 µg XG-102 as compared with the vehicle delivery (from 1.067 ± 0.037 to 0.100 ± 0.065; 
42 
43 Fig 4C). 
45 
46 In order to confirm the reduced recruitment of inflammatory cells after XG-102 treatment, the 
47 
48 expression of CINC-1, a mediator of neutrophil infiltration in the inflammatory sites, was evalu- 
49 
50 
51 ated in retinal cells at the mRNA level. As compared with the control group, the IV injection of 
52 
53 35 µg of XG-102 reduced the CINC-1 expression from 0.382 ± 0.035 to 0.205 ± 0.063 (Fig 5A). 
54 
55 The decrease of CINC-1 mRNA was also observed after IVT injection of 0.2 µg of XG-102, from 
56 
57 
58 0.584 ± 0.150 to 0.202 ± 0.063 as compared with the vehicle-injected eyes (Fig 5B). The SCJ 
59 
60 
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1 
2 
3 injection of 1.8 µg of XG-102 led to a down-regulation of CINC-1, from 1.05 ± 0.43 to 0.18 ± 
4 
5 
6 0.03 as compared with the vehicle. However, in uninjected eyes no diminution of CINC-1 ex- 
7 
8 pression was observed after SCJ administration of 1.8 µg-XG-102 (Fig 5C). These results go 
9 
10 hand in hand with the decrease in PMNs infiltration in the eyes treated with: 35 µg-XG-102 IV, 
11 
12 
13 0.2 µg-XG-102 IVT and 1.8 µg-XG-102 SCJ injections (Fig 3). 
14 
15 
16 
17 
18 Discussion 
19 
20 
21 The JNK pathway is activated in inflammatory reactions in various tissues of the body, particu- 
22 
23 larly the central nervous and the digestive systems [16,17]. Its specific inhibition by XG-102 
24 
25 blocks the phosphorylation of its nuclear target, c-Jun, which prevents the transcription of pro- 
26 
27 
28 inflammatory cytokines/chemokines and the activation of the intracellular processes with harmful 
29 
30 results, such as cellular death by apoptosis [12, 18, 19]. In this study, we demonstrated that XG- 
31 
32 102 exerts anti-inflammatory effects on EIU using IV and IVT, as already shown in our previous 
34 
35 study [12], but also using SCJ injections. XG-102 is efficient at low-doses; since the 0.08 µg dose 
36 
37 directly injected into the vitreous was already efficient andincreasing the dose did not increase 
38 
39 
40 the effect. The anti-inflammatory activity was confirmed by reduced cell infiltration in ocular 
41 
42 tissues and decreased expression of iNOS and CINC-1 using specific dose for each tested route of 
43 
44 administration. Importantly, the anti-inflammatory effect correlated with the decreased phosphor- 
45 
46 
47 ylation of JNK, demonstrating the specific mechanism of action of this drug. 
48 
49 
50 For clinical used, SCJ injection of a D-peptide is particularly interesting. This route of admin- 
51 
52 istration is minimally invasive, with no risk of possible infection associated with IVT injections. 
53 
54 
55 Moreover, XG-102 has a long half-life in vivo due to its resistance from proteases limiting the 
56 
57 need for re-injections [20]. SCJ of 1.8µg was the lowest dose efficient clinically and biologically. 
58 
59 
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1 
2 
3 At 22 µg, the uninjected contralateral eye also showed reduced inflammation, suggesting a sys- 
4 
5 
6 temic diffusion of XG-102 after SCJ in the treated eye. However, at a lower dose of 1.8 µg, no 
7 
8 effect was observed on the contralateral eye, suggesting a direct transscleral passage of XG-102 
9 
10 after SCJ without systemic diffusion. XG-102 is a small peptide with a molecular weight of 
11 
12 
13 around 2.2 kDa adapted for transscleral diffusion. Indeed, previous works have shown that hy- 
14 
15 drophilic molecules up to 150 kDa were able to cross the sclera, the scleral permeability being 
16 
17 inversely proportional to the molecular weight [21]. Whether direct trans-corneal penetration of 
 
19 
20 XG-102 is occurring remains to be demonstrated. Sub-conjunctival injections are rarely used and 
21 
22 no drug is approved for such injections. However, studies comparing the ocular media levels of 
23 
24 Dexamethasone phosphate after oral administration, latero bulbar or sub-conjunctival injections 
26 
27 in humans, found that the highest concentrations in aqueous and vitreous humors were achieved 
28 
29 after SCJ injections.[22,23,24]. 
30 
31 
32 This is to our knowledge the first study evaluating the effect of sub-conjunctival injection of a 
34 
35 peptide for the treatment of uveitis. We have performed a first phase IIa clinical trial (EudraCT 
36 
37 Number:  2012-001510-14)  to  evaluate  the  safety  and  tolerance  of  XG-102  injected  sub- 
38 
39 
40 conjunctivally in patients with post-operative inflammation. 
41 
42 
43 XG-102 injected either sub-conjunctivally or direclty in the eye could be used in many ocular 
44 
45 diseases, associated with intraocular inflammation and/ or excitotoxicity. 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801 
 
Journal of Ocular Pharmacology and Therapeutics Page 16 of 23  
7 
3
 
 
 
1 
2 
3 References 
4 
5 
6 1. De Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani- 
8 
9 Asenbauer T, LeHoang P, Lightman S. Understanding uveitis. The impact of research on visual 
10 
11 outcomes. ProgRetin Eye Res 2011Nov; 30 (6):452-470. 
12 
13 
14 2. Mercieca K, Jones NP. Treatment of acute anterior uveitis in the community, as seen in an 
15 
16 emergency eye centre.A lesson for the general practitioner?. European Journal of General Prac- 
17 
18 tice 2012 Mar; 18(1):26-9. 
19 
20 
21 3. Medeiros R, Rodrigues GB, Figueiredo CP, Rodrigues EB, Grumman A Jr, Menezes-de-Lima 
22 
23 O Jr, Passos GF, Calixto JB.Molecular mechanisms of topical anti-inflammatory effects of lipox- 
24 
25 in A(4) in endotoxin-induced uveitis. Mol Pharmacol 2008 Jul; 74:154-161. 
26 
27 
28 4. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. 
29 
30 Ophthalmologica 2010; 224(1):46-53. 
31 
32 5. Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in diagnosis and management 
34 
35 of anterior uveitis. Indian J Ophthalmol 2010; 58(1):11-19. 
36 
37 6. Abad S, Sève P, Dhote R, Brézin AP. Uvéites et médecine interne. Stratégiesdiagnostique et 
38 
39 
40 thérapeutique. La Revue de médecine interne 2009 Jun; 30(6):492–500. 
41 
42 7. De Smet MD. Corticosteroidintravitreal implants. Dev Ophthalmol 2012; 51:122-133. 
43 
44 8. Tsai ML, Horng CT, Chen SL, Xiao X, Wang CH, TsaoYP. Suppression of experimental uvei- 
45 
46 
47 tis by a recombinant adenoassociated virus vector encoding interleukin-1 receptor antagonist. 
48 
49 Molecular Vision 2009; 15:1542-1552. 
50 
51 9. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal ki- 
52 
53 nase in rheumatoid arthritis. J Pharmacol Exp Ther 1999 Oct;291(1):124-130. 
54 
55 
56 
57 
58 
59 
60 
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801 
 
Page 17 of 23 Journal of Ocular Pharmacology and Therapeutics  
3
 
 
 
1 
2 
3 10. Clancy R, Rediske J, Koehne C, Stoyanovsky D, Amin A, Attur M, Iyama K, Abramson 
4 
5 SB.Activation of stress-activated protein kinase in osteoarthritic cartilage. Evidencefor nitric ox- 
6 
7 ide dependence. Osteoarthritis Cartilage 2001; 9(4):294-299. 
8 
9 11. Hirt L, Badaut J, Thevenet J, Granziera C, Regli L, Maurer F, Bonny C, Bogousslavsky J.D- 
10 JNKI1, a Cell-Penetrating c-Jun-N-Terminal Kinase Inhibitor, Protects Against Cell Death in 11 
12 Severe Cerebral Ischemia. Stroke 2004; 35:1738-1743. 
13 
14 12. Touchard E, Omri S, Naud MC, Berdugo M, Deloche C, Abadie C, Jonet L, Jeanny JC, 
15 
16 Crisanti P, De Kozak Y, Combette JM, Behar-Cohen F. A peptide inhibitor of c-jun N-terminal 
17 
18 
19 kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sc 2010; 51:4683- 
20 
21 4693. 
22 
23 13. Rosenbaum JT, McDevitt HO, Guss RB, Egbert R. Endotoxin-induced uveitis in rats as a 
24 
25 
26 model for human disease. Nature 1980; 268:611-613. 
27 
28 14. Hashida M, Fukushima A, Zhang J, Kodama H, Ueno H. Involvement of superoxide generat- 
29 
30 ed by polymorphonuclear leukocytes in endotoxin-induced uveitis. Graefe’s Arch Clin Exp Oph- 
32 
33 thalmol 2000; 238:359–365. 
34 
35 15. Behar-Cohen FF, Parel JM, Pouliquen Y, Thillaye-Goldenberg B, Goureau O, Heydolph S, 
36 
37 
38 Courtois Y, De Kozak Y. Iontophoresis of dexamethasone in the treatment of endotoxin-induced- 
39 
40 uveitis in rats. Exp Eye Res 1997; 65(4):533-545. 
41 
42 16. Ip YT, DavisRJ.Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation 
43 
44 
45 to development. Current Opinion in Cell Biology 1998; 10(2):205-219. 
46 
47 17. Willaime-Morawek S, Brami-Cherrier K, Mariani J, Caboche J, BruggB.C-Jun N-terminal 
48 
49 kinases/c-Jun and p38 pathwayscooperate in ceramide-induced neuronal apoptosis. Neuroscience 
50 
51 
52 2003; 119(2):387-397. 
53 
54 18. Chi ZL, Hayasaka S, Zhang XY, Cui HS, Hayasaka Y. A cholinergic agonist attenuates endo- 
55 
56 toxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2007; 48(6):2719-2725. 57 
58 
59 
60 
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801 
 
Journal of Ocular Pharmacology and Therapeutics Page 18 of 23  
1
 
3
 
 
 
1 
2 
3 19. Reinecke K, Eminel S, Dierck F, Roessner W, Kersting S, Chromik AM, Gavrilova O, 
4 
5 
6 Laukevicience A, Leuschner I, Waetzig V, Rosenstiel P, Herdegen T, Sina C. The JNK Inhibitor 
7 
8 XG-102 Protects against TNBS-Induced Colitis. PLoS One 2012 Mar; 7(3):e30985. 
9 
10 20. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-Permeable Peptide Inhibitors of 
11 
12 
13 JNK Novel Blockers of β-Cell Death. Diabetes 2001; 50(1):77-82. 
14 
15 21. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein 
16 
17 delivery for retinal diseases. From basic considerations to clinical applications. ProgRetin Eye 
 
19 
20 Res 2010 Nov; 29(6):443-465. 
21 
22 22. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, van Meurs JC. 
23 
24 High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. 
25 
26 Am J Ophthalmol 1999; 128(2):192-197. 
27 
28 23. Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, van Meurs 
29 
30 JC.Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthal- 
31 
32 mol 1998; 125(5):673-679. 
33 
34 24. Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, van 
36 
37 MeursJC.Peribulbar corticosteroid injection. Vitreal and serum concentrations after dexame- 
38 
39 thasone disodium phosphate injection. Am J Ophthalmol 1997 Mar; 123(3):358-363. 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801 
 
Page 19 of 23 Journal of Ocular Pharmacology and Therapeutics  
1
 
2
 
4
 
 
 
1 
2 
3 Legends 
4 
5 
6 
7 
8 Figure 1: Clinical evaluation of XG-102 efficacy in Endotoxin-Induced Uveitis. 
9 
10 Clinical scores (mean ± SEM arbitrary units, a.u.) were evaluated at the peak of the disease, 24 
11 
12 
13 hours after intravenous (IV, A; n≥8 eyes per group), intravitreal (IVT, B; n≥4 eyes per group) 
14 
15 and sub-conjunctival (SCJ, C; n≥5 eyes per group) injections of different doses of XG-102. Dex- 
16 
17 amethasone phosphate IV (n=6), IVT (n=5) or SCJ (n=5) injections were used as positive control. 
 
19 
20 Comparisons were respectively made with vehicle IV (n=8), IVT (n= 12) or SCJ (n=6) injections. 
21 
22 Clinical signs of uveitis were significantly reduced after: (A) IV injections of 35 µg (*) and 355 
23 
24 µg (***) of XG-102; (B) IVT injections of 0.08 (**), 0.2 (**) and 2.2 µg (**) of XG-102; (C) 
26 
27 SCJ injections of 1.8 µg (*) and 22 µg (**) of XG-102. No statistical difference (ns) was ob- 
28 
29 served between the clinical scores of the IV-injected 355 µg, the SCJ-injected 22 µg and all the 
30 
31 
32 IVT-injected doses and those of the Dexamethasone phosphate groups for the respective routes of 
33 
34 administration. *P<0.05, **p<0.01, ***p<0.001. 
35 
36 
37 
38 
39 Figure 2: Analysis of c-Jun phosphorylation in “RPE-choroid-sclera” complex. 
40 
41 Western blots were performed 24 hours after intravenous (IV of 35 µg, A), intravitreal (IVT of 
42 
43 0.2 µg, B) and sub-conjunctival (SCJ of 1.8 µg, C) injections of XG-102, and compared to the 
45 
46 vehicle-injected eyes (n=2 pooled “RPE-choroid-sclera” complex per group). The immunoblots 
47 
48 (top) of Phospho c-Jun [Ser 63] and of the α-tubulin reporter protein, and their quantization by 
49 
50 
51 densitometry (bottom) demonstrated that the phosphorylation of c-Jun was strongly reduced by 
52 
53 XG-102 delivered by the three routes of administration. 
54 
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1 
2 
3 Figure 3: Effect of XG-102 on PMN cells infiltration in ocular tissues. 
4 
5 
6 Polymorphonuclear (PMN) leukocytes infiltration was evaluated 24 hours after EIU induction in 
7 
8 eyes treated with 35 µg-XG-102 IV (A), 0.2 µg-XG-102 IVT (B) and 1.8 µg-XG-102 SCJ (C) 
9 
10 injections on frozen sections (3 eyes per group, 3 sections per eye). 
11 
12 
13 
14 
15 
16 
17 Figure 4: Effect of XG-102 on iNOS expression in neuroretinal cells. 
19 
20 Mean ± SEM relative band intensity were determined after the detection of iNOS expression in 
21 
22 retinal cells of the eyes treated with 3.2 µg and 35 µg of XG-102 IV (A, n≥3), 0.2 µg and 2.2 µg 
23 
24 of XG-102 IVT (B, n≥2) and 1.8 µg XG-102 SCJ (C, n=3) injections and compared with those of 
26 
27 the control vehicle-injected eyes, 24 hours after EIU induction. Representative RT PCR products 
28 
29 visualized by ethidium bromide staining are shown in the bottom plan.*P<0.05. 
30 
31 
32 
33 
34 Figure 5: Effect of XG-102 on CINC-1 expression in neuroretinal cells. 
35 
36 Mean ± SEM relative band intensity were determined after the detection of CINC-1 expression in 
37 
38 
39 retinal cells of the eyes treated with 35 µg of XG-102 IV (A, n≥2), 0.2 µg of XG-102 IVT (B, 
40 
41 n≥3) and 1.8 µg-XG-102 SCJ injection (n≥3) and compared with that of vehicle control eyes, 24 
42 
43 hours after EIU induction. Representative RT PCR products visualized by ethidium bromide 
45 
46 staining are shown in the bottom plan. 
47 
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